IBS-C Study A2306

ISRCTN	ISRCTN47368803
DOI	https://doi.org/10.1186/ISRCTN47368803
Protocol serial number	CHTF919A2306
Sponsor	Novartis Pharmaceuticals Corporation
Funder	Sponsored by Novartis Pharmaceuticals Corporation (http://click.atdmt.com/GTO/go/thbmbnov00700895gto/direct/01/)

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Ms Marisa Carmen
Scientific

Novartis Pharmaceuticals
One Health Plaza
East Hanover
07936
United States of America

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Scientific title
Study objectives	Not provided at time of registration.
Ethics approval(s)	Not provided at time of registration.
Health condition(s) or problem(s) studied	Irritable bowel syndrome (IBS) with constipation
Intervention	Not provided at time of registration.
Intervention type	Other
Primary outcome measure(s)	Not provided at time of registration.
Key secondary outcome measure(s)	Not provided at time of registration.
Completion date	30/04/2003

Participant type(s)	Patient
Age group	Adult
Lower age limit	18 Years
Sex	Female
Key inclusion criteria	Females, 18 to 65 years, with IBS-C (Irritable Bowel Syndrome with constipation)
Key exclusion criteria	Not provided at time of registration.
Date of first enrolment	01/04/2002
Date of final enrolment	30/04/2003

Novartis Pharmaceuticals

East Hanover
07936
United States of America

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan